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Abstract
Background—Low pulmonary function (PF) is associated with poor cognitive function and
dementia. There are few studies of change in PF in mid-life and late-life cognitive status.
Design and Participants—We studied this is 3,665 subjects from AGES-Reykjavik Study who
had at least one measure of forced expiratory volume/ 1 sec (FEV1) and were cognitively tested on
average 23 years later. A subset of 1,281 subjects had two or three measures of FEV1 acquired
over a 7.8 year period. PF was estimated as FEV1/Height2. Rate of PF decline was estimated as
the slope of decline over time. Cognitive status was measured with continuous scores of memory,
speed of processing, and executive function, and as the dichotomous outcomes of mild cognitive
impairment (MCI) and dementia.
Results—Lower PF measured in mid-life predicted lower memory, speed of processing,
executive function, and higher likelihood of MCI and dementia 23 years later. Decrease of PF over
a 7.8-year period in mid-life was not associated with lower cognitive function or dementia.
Conclusion—Reduced PF measured in mid-life may be an early marker of later cognitive
problems. Additional studies characterizing early and late PF changes are needed.
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INTRODUCTION
Poor pulmonary function leads to a reduced oxygen supply to the brain.1,2 Lower pulmonary
function (PF) has been correlated with poor cognitive performance in patient populations as
well as in community dwelling subjects with a wide range of health status and ethnicities.1–7
PF has also been shown to be consistently reduced in demented subjects in cross-sectional
studies,8 and is associated with a future risk for dementia.9–11 These extant studies, based on
one measure of PF, may well reflect the strong constitutional and early life environmental
factors that affect PF.12 There are few data on whether a decline in PF in mid-life also
contributes to late-life cognitive test scores and risk for MCI and dementia. If change, in
addition to level of PF, is also associated with cognition, this would strengthen the evidence
that PF has a more direct effect on cognition. This is important to study as preventing poor
PF with early interventions, such as education campaigns to stop smoking or increase
physical activity, or by treating and preventing pulmonary diseases may reduce late-life
cognitive impairment.
METHODS
The population-based AGES-RS study (2002–2006) cohort (5764 men and women) is based
on surviving members of the Reykjavik Study initiated in 1967 by the Icelandic Heart
Association to prospectively study cardiovascular disease in Iceland.13 The Reykjavik Study
included a random sample of men and women born between 1907 and 1935 and living in
Reykjavik area. By design, sub-cohorts of subjects were examined from one to six times
from 1967 to 1996.13
Pulmonary assessment at mid-life
PF was evaluated at each Reykjavik Study examination with Vitalograph Spirometers
(Vitalograph Ltd., Buckingham, UK). The same equipment was used throughout the study
and was regularly calibrated with a 1 liter syringe. Three attempts were recorded for each
forced expiratory volume in 1 s (FEV1). PF was calculated as FEV1 divided by height
squared of the subject, as this has been shown in this cohort to be a more stable predictor of
outcomes than FEV1 alone.14 Height was taken at the time the first spirometry measure was
acquired. In analyses using repeat measures of spirometry we used the same baseline height
so FEV1/height2 did not appear to change because of a change in height.
Assessment of cognition, and dementia and MCI later in life (2002–2006)
Cognitive assessment in AGES-RS study has already been detailed.15 In brief, we
administered a battery of six different cognitive tests that included a modified version of the
California Verbal Learning Test,16 the Figure Comparison Test,17 the Digit Symbol
Substitution Test,18 the Stroop Test,19 a shortened version of the Cambridge
Neuropsychological Test Automated Battery Spatial Working Memory test,20 and the Digits
Backward test.18 From these tests, three cognitive domain composite Z-scores were
calculated: memory, speed of processing and executive function.15
Dementia case ascertainment was a three-step process previously described13 that included a
screening based on the Mini-Mental State Examination and the Digit Symbol Substitution
Test, a diagnostic neuropsychological test battery, an informant interview, and a
neurological examination. A consensus diagnosis of dementia and MCI was made by a panel
including a geriatrician, neurologist, neuropsychologist, and neuroradiologist. Dementia was
classified according to DSM-IV criteria.21 MCI was defined as having a borderline score
(i.e.< −1.5 SD scores based on the distribution of scores in a cohort sub-sample) in at least
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one cognitive domain or as having one abnormal test result in at least two other domains not
severe enough to be classified as dementia.22
Potential confounding and moderating variables
In addition to age and sex, analyses were adjusted for factors associated with both PF and
cognitive outcomes.23 Variables measured concurrently with the first PF measure included
education level (> high school yes/no), occupation (manual, intermediate and professional),
BMI and moderate to vigorous physical activity in youth and midlife. Variables measured in
the late-life exam concurrently with cognition included: presence of depressive symptoms
measured by the 15-point Geriatric Depression Scale;24 self-reported history of a doctor’s
diagnosis of coronary heart disease; chronic obstructive pulmonary disease (COPD);
hypertension by doctor’s report, use of anti-hypertensive medication, or measured systolic
and diastolic blood pressure; diabetes by doctor’s report, use of anti-diabetic drugs, or
fasting glucose levels; and life-time history of smoking (never, former, current).
Based on previous reports we investigated whether presence of the Apolipoprotein E ε*4
allele,25 a genetic susceptibility factor for dementia, modified the association of PF to
dementia. Apolipoprotein E (Apo E) genotype was determined by standard DNA
amplification and a restriction isotyping method.26 Subjects were classified as having no
Apo E ε4 alleles or having 1 or 2 Apo E ε4 alleles.
Analytical sample
We excluded baseline spirometry assessments made before March 1, 1976 (n=1,522)
because, as described previously, there were a significant number of outlier measurements
from that period;14 measures made between 1991 and 1996 (n=51) by subjects who were
older than 70 years of age;13 subjects with no PF assessments (n=8), and those with
incomplete cognitive data (n=518). These exclusions resulted in an analytical sample of
3,665 subjects with complete data on PF and cognitive status (see supplemental figure).
Compared to subjects not included in the analysis, those included were younger, more likely
to be women, were less likely to be depressed or smokers and more often had a manual
occupation.
The 3,665 included 128 MCI and 288 demented subjects. Of the 3,665, 1,281 subjects (of
which 1,151 were not demented or had MCI) had multiple PF assessments to estimate
change in PF; 874 subjects had two and 407 had three assessments. Differences between
those with one compared to those with multiple measures are shown in supplementary table
1. Analyses on cognitive domains included only subjects with no dementia or MCI (n=3,249
for the first PF assessment and n=1,151 for the change in PF); analyses on dementia and
MCI included all subjects (n=3,665 for the first PF assessment and n=1,281 for the change
in PF).
Statistical analysis
For the baseline analyses, descriptive comparisons and hypothesis testing were examined by
quartile of PF, using analysis of variance or logistic regression. The change in PF was
estimated by the coefficient of PF linearly regressed against age in each of the 1281 subjects
who had at least two pulmonary assessments corresponding to the change in FEV1 per year.
The change results are expressed as the change in cognitive score, or likelihood of dementia
or MCI associated with each standard deviation change in PF. All models were first adjusted
for age and sex (Model 1) and then further adjusted for the aforementioned potential
confounders (Model 2). We entered into model 1, the PF and Apo E ε4 main effect terms
and their cross product to test the interaction between the two variables. Analyses were
Vidal et al. Page 3
J Am Geriatr Soc. Author manuscript; available in PMC 2014 January 01.
$watermark-text
$watermark-text
$watermark-text
conducted with the statistical software package SAS Version 9.1 (SAS Institute Inc., Cary,
N.C., USA). In all analyses, the 2 sided α–level of 0.05 was considered significant
RESULTS
The sample of 3,665 subjects had a mean age of 76 years and 33 percent were male. Mean
age at the first spirometry assessment was 52 years (SD 5.3), which was on average 23 years
prior to the cognitive assessment. Low FEV1/height2 was associated with older age, lower
education, less mid-life physical activity; and presence of COPD, diabetes, high blood
pressure and smoking (Table 1). Among subjects with multiple PF assessments, PF
decreased by an average of 1.9% per year.
Level of PF and cognition
Among the 3, 249 non-demented subjects, performance in the three cognitive domains
increased as FEV1/height2 quartile increased (P for linear trend < 0.001 for all three
cognitive domains). Coefficients were slightly attenuated after adjustments for demographic
and cardiovascular risk factors and disease (Model 2, Table 2). The interaction between the
presence of Apo E ε4 and PF was not significant (P >0.15) for any of the cognitive domains.
The prevalence of dementia among the 3,665 subjects was 5.6 percent in the lowest quartile
of FEV1/height2 and 1.9 percent in the highest FEV1/height2 quartile (Table 1) and the
prevalence of MCI was 10.5 and 4.8 percent respectively. Mean FEV1/height2 was 0.93
(SD=0.22) in dementia cases, 0.97 (0.20) in MCI cases, and 1.01 (0.20) in the other subjects.
For every increase of one SD of FEV1/height2, there was a decreased likelihood of MCI
(0.78 (95% confidence interval, 0.68, 0.89) or dementia (0.68; 0.55, 0.83).(Table 2). The
Apo E ε4 and PF interaction was not significant for the presence of dementia or MCI
(P=0.64).
Change in pulmonary function
For the 1,281 subjects (1,151 with no MCI or dementia) with at least two assessments of PF,
the mean loss of FEV1/Height2 was 1.92 (1.61) percent per year, over an average 7.8-year
(2.6) period (total loss of 14.3 percent). In this sub-sample, the association of the baseline
FEV1/height2 to cognition was similar to that in the total sample (memory: β=0.08
(SE=0.03), P=0.02, speed: β=0.06 (SE=0.03), P=0.02 and executive function: β=0.10
(SE=0.03), P=0.003). However, there were no significant associations of change in FEV1/
Height2 to memory (P=0.88), speed of processing (P=0.80) or executive function (P=0.97)
among the non-demented subjects (Table 2). Compared to the normal subjects, subjects with
MCI had a smaller decline in PF (P=0.04); no relationship was found with dementia
(P=0.39).
DISCUSSION
We found subjects with lower FEV1/height2 at mid-life were more likely, 23 years later, to
have lower cognitive test scores or to develop MCI or dementia. Adjustments for a range of
factors associated with cerebro-vascular disease or PF, including smoking status, mid-life
physical activity and occupation, and late-life COPD attenuated the association of PF to
memory, but otherwise did not change the associations of interest. The change in PF over a
7.8-year period was, however, not significantly associated with our cognitive outcomes, with
the exception of subjects with MCI, who had a smaller change in PF on average than the
subjects who were not MCI or demented.
Strengths of this study include a particularly well-described cohort13 and the availability of
multiple cognitive test-scores, aggregated into three normally distributed cognitive
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domains.15 The dementia and MCI assessment was a multidisciplinary process that was
based on a standardized adjudication process.13 Pulmonary assessments were made
according to a standardized protocol administered on average 23 years before the measure of
cognitive status. Variability due to the spirometry equipment was minimized by maintaining
and using the same equipment over time. Not only does this give us insight into early PF
characteristics of persons with later cognitive decline it also reduces the error introduced to
PF measures when subjects are cognitively impaired and may not be able to fully comply
with the protocol. We were also able to control for important confounding factors including
cardiovascular risk factors and disease, although residual confounding cannot be excluded.
The predictive value of mid-life PF for cognitive performance later in life has been reported
elsewhere.9–11 Based on previous studies on this topic the mechanism through which PF
may affect cognitive function is generally thought to be related to poor oxygen supply to the
brain. The brain only accounts for 2% of the total body weight, yet it consumes 20% of the
body energy,27 almost exclusively through complete oxidation of glucose.28 Subtle
variations of the cerebral blood flow and oxygen saturation are likely to have a significant
effect on brain function. Moreover, PF doesn’t only reflect lung disease, but also heart
disease and other vascular disorders, which in turn could be the cause of cognitive deficits
by themselves. However, studies suggest the mechanism is complicated by the complex
effects of constitutional and environmental factors that both contribute to pulmonary and
cognitive development.29,30 Indeed, a relationship between PF and cognition can already be
observed very early in life, among pre-teens31 and young adults.5 In the British 1946 birth
cohort,32 the relationship between PF at 43 years old and the cognitive ability 10 years later
was no longer significant when the model was adjusted for cognitive ability at 15 years old
suggesting the importance of early life exposures and experiences on late-life functioning.
Emery et al. found in the cross-twin correlation analyses of 222 Swedish twin pairs, that
FEV1 was associated with cognition at baseline and six years later, and concluded that the
genetic effects accounted for more than the environmental effects.12
We found no association between change in PF and late life cognitive scores. Apart from
constitutional factors, other factors may explain this lack of association. Our follow-up
duration of 7.8 years may have been too short to capture an association, even though PF
decreased by 1.9% per year, which is slightly higher than the 1% per year reported in the
literature for non-smoking adults.33 The change in PF was measured on average 23 years
before the cognitive assessment and patterns of differential change during the interval may
have obscured the relationship. Also, since PF predicts mortality in this cohort,14 survival
effects may also play a role. For instance, if subjects with fast declining PF died earlier than
those with slower declines in PF, those potentially at the highest risk for cognitive
impairment would not have survived to the AGES-RS baseline. Lastly, two measurement
issues that could have influenced the results are regression to the mean and a ‘floor effect’.
Regression to the mean would overall reduce the amount of change PF and a floor effect
would truncate the change because subjects with low baseline PF could not substantially
decline. These measurement errors may explain the finding that persons with MCI had a
slower rate of decline in PF than cognitively normal subjects.
In summary this study shows, subjects with lower mid-life PF had on average lower
cognitive scores, and were more often diagnosed with MCI and dementia 23 years later. On
the other hand the decrease of PF at mid-life was not associated with cognitive performance,
MCI or dementia. These data suggest early efforts to maintain pulmonary health may have a
positive influence on late life cognition.
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Refer to Web version on PubMed Central for supplementary material.
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